NOsocomial Dissemination Risk of SARS-Cov2

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

2523 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-04-17

Study Completion Date

2020-07-12

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To date, in France, in the context of the SARS Cov2 pandemic,both the number of affected subjects and the number of severe forms requiring hospital care are increasing.

Several nosocomial transmission clusters have already been identified in hospitals (both pediatric and adult) but there is still limited data on the nosocomial spread of SARS-Cov2.

This nosocomial transmission affects both patients and caregivers. It is important to understand the spread of the virus within the hospital. This will help to optimize procedures to prevent transmission to caregivers and hospitalizedpatients not infected with SARS Cov2, and more generally this will contribute to control the spread of SARS Cov2 in the community

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

It is an observational study without any risk. Every participating service will be investigated for 2 consecutive days .

* At each staff rotation, an individualsensorwill be provided toall thestaff(caregivers, administrative, students etc…) to be worn duringtheirworking hours. Also a sensor will be placed at each patient's bedside.
* In addition, epidemiological data relating to socio-demographic characteristics, profession, protective measures will be collectedfrom hospitalstaff. Also, some data from the 'entrepot des données de santé" regarding individual carepathways in the hospitalwill be extracted.
* A map of the unit, specifying the location of each patient will be made.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sars-CoV2

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Informed of the purpose of the study and having expressed his non-opposition or of a relative (if the patient's state of health does not allow it)
* Hospitalized in one of the participating departments

* Informed of the objective of the study and having expressed his no opposition
* Having daily contact with patients hospitalized in participating departments

* Informed of the purpose of the study and having expressed his non-opposition
* Having daily contacts with patients hospitalized in the participating departments

Exclusion Criteria

* Refuse to participate

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Didier Guillemot

Garches, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

APHP200417

Identifier Type: -

Identifier Source: org_study_id